# Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients

> **NCT05338736** · — · COMPLETED · sponsor: **University Magna Graecia** · enrollment: 45 (actual)

## Conditions studied

- SARS CoV 2 Infection
- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)
- **DIAGNOSTIC_TEST:** LIAISON SARS-CoV2-IgM (DiaSorin)
- **DIAGNOSTIC_TEST:** Human IFN-g ELISpot PLUS (ALP) (AUROGENE)

## Key facts

- **NCT ID:** NCT05338736
- **Lead sponsor:** University Magna Graecia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2022-05-27
- **Final completion:** 2022-05-27
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05338736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05338736, "Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05338736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*